Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Genitourinary 1

Conditions

Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × cabiralizumab × Clear all
NCT03502330 2024-07-03

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Yale University

Phase 1 Completed
42 enrolled 17 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT03431948 2023-02-16

C4-MOSART

University of Chicago

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡